Home › Funds › Spruce Street Capital LP › ANRO
Spruce Street Capital LP position in ANRO
ALTO NEUROSCIENCE INC · Health Care
Spruce Street Capital LP reported holding 1,676,558 shares of ANRO (ALTO NEUROSCIENCE INC) in its Q3 2026 13F filing — a position valued at US$42.8M, representing 6.81% of its reported portfolio and ranking #4 among its reported holdings. Spruce Street Capital LP has disclosed ANRO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's ANRO position evolved
Spruce Street Capital LP first disclosed a stake in ANRO in Q4 2025 at 222,844 shares (US$4.0M). The position peaked in Q3 2026 at 1,676,558 shares, worth US$42.8M. Across 4 filings, Spruce Street Capital LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,676,558 shares valued at US$42.8M — an increase of 323,511 shares quarter over quarter.. Notable position changes include a 495% increase in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 222.84K | $3.97M | New |
| Q1 2026 | 1.33M | $29.12M | Add |
| Q2 2026 | 1.35M | $35.71M | Add |
| Q3 2026 | 1.68M | $42.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANRO and 13F data
ANRO (ALTO NEUROSCIENCE INC) is a Health Care company. 62 other funds we track also report a position in ANRO — the largest reported positions include Alpha Wave Global, LP (US$94.7M), Commodore Capital LP (US$71.9M), PERCEPTIVE ADVISORS LLC (US$42.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANRO
- Alpha Wave Global, LP 3.71M sh · $94.66M · Q3 2026
- Commodore Capital LP 2.72M sh · $71.87M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.61M sh · $42.49M · Q2 2026
- Vivo Capital, LLC 1.36M sh · $34.72M · Q3 2026
- ARMISTICE CAPITAL, LLC 864.00K sh · $22.80M · Q2 2026
- Vestal Point Capital, LP 785.00K sh · $20.72M · Q2 2026
- 72 Investment Holdings, LLC 667.78K sh · $17.62M · Q2 2026
- Affinity Asset Advisors, LLC 643.34K sh · $16.42M · Q3 2026
- Venrock Adviser, LLC 500.00K sh · $13.20M · Q2 2026
- Parkman Healthcare Partners LLC 429.04K sh · $11.32M · Q2 2026
- Ikarian Capital, LLC 407.34K sh · $10.75M · Q2 2026
- Saturn V Capital Management LP 182.83K sh · $4.82M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held ANRO?
Spruce Street Capital LP has disclosed ANRO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in ANRO?
As of Q3 2026, Spruce Street Capital LP holds 1.68M shares of ANRO (ALTO NEUROSCIENCE INC), valued at $42.80M, representing 6.81% of its reported portfolio and ranking #4.
Has Spruce Street Capital LP been buying or selling ANRO?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP increased its position in ANRO. The position peaked in Q3 2026 at 1.68M shares.
Which other funds hold ANRO?
Other major institutional holders of ANRO include Alpha Wave Global, LP, Commodore Capital LP, PERCEPTIVE ADVISORS LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.